Bringing it all Together for Commercialisation Pt.3

In the last of our three part fireside chat with Paul Wu, Director of Upstream Processing at Bayer HealthCare, Guenter Jagschies, Senior Director at GE Healthcare Life Sciences, Ali Siahpush, Founder of Pharmefex and VP of Product development at Dendreion and lastly Katherine Chaloupka, Senior Scientist at Amgen discuss commercialisation in the bioprocess industry.

Catch up on part one here

Brian Caine, co-founder and publisher of Bioprocess International Magazine sets out the topics of discussion for the fireside chat, “Bringing it all Together for Commercialisation – perspectives from every stage.”

The main topics covered:

  • Business models involving bioprocess, analytical, formulation and delivery that accelerate end-to-end development.
  • How platforms, process characterization and validation can improve cycle times for clinical commercial production.
  • Technologies and approaches aimed at reducing time needed for process and product development, in addition to reducing cost to clinic.
  • Efforts in flexible manufacturing and single-use; strategies and opportunities in strategic outsourcing for bringing it all together.

Watch part three of our fireside chat below.

1 thought on “Bringing it all Together for Commercialisation Pt.3”

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s